t e C h n I C a l r e p O r t S Channelrhodopsins (ChRs) are used to optogenetically depolarize neurons. We engineered a variant of ChR, denoted red-activatable ChR (ReaChR), that is optimally excited with orange to red light (l ~590-630 nm) and offers improved membrane trafficking, higher photocurrents and faster kinetics compared to existing red-shifted ChRs. Red light is less scattered by tissue and is absorbed less by blood than the blue to green wavelengths that are required by other ChR variants. We used ReaChR expressed in the vibrissa motor cortex to drive spiking and vibrissa motion in awake mice when excited with red light through intact skull. Precise vibrissa movements were evoked by expressing ReaChR in the facial motor nucleus in the brainstem and illumination with red light through the external auditory canal. Thus, ReaChR enables transcranial optical activation of neurons in deep brain structures without the need to surgically thin the skull, form a transcranial window or implant optical fibers.
ChRs are light-gated, non-specific cation channels that allow the selective depolarization of genetically targeted cells [1] [2] [3] [4] [5] [6] . However, currently available ChRs are limited by action spectra that typically peak at 450-545 nm [7] [8] [9] [10] [11] . In mammalian systems, such blue-green wavelengths have limited penetration depths into neural tissue 12 , as they are strongly absorbed by endogenous chromophores such as flavins, hemoglobin and melanin, and they are scattered more strongly than yellow-red wavelengths. A common means to circumvent this attenuation and achieve deep ChR excitation is to insert a thin optical fiber into the target neural tissue 13 . However, this invasive procedure requires precise stereotaxic positioning that may be difficult to perform when ChR is expressed in subcortical nuclei, and the fiber may damage neuronal and/or vascular structures en route to the target. The practical issue of efficient light delivery can be solved by creating a red-shifted ChR with spectral peaks near or above 600 nm, where light absorption by hemes and scattering cross-sections drop off steeply 12 . Such ChRs could facilitate the stimulation of deep structures with a light source placed outside the tissue or region of interest and thus mitigate the need for invasive stimulation.
In this study, we engineered a new variant of ChR that we named ReaChR for red-activatable ChR. Compared to the previously described ChRs with red spectral shifts VChR1 (ref. 14) and C1V1 E122T (ref. 11) , ReaChR has improved membrane trafficking and expression in mammalian cells, a more robust spectral response above 600 nm and an enhanced steady-state response to light with wavelengths longer than 600 nm. When ReaChR was expressed in the mouse vibrissae motor cortex (vM1), we could trigger temporally precise neuronal responses by illumination of the cortical surface with 617 nm light through a transcranial window or evoke vibrissae movements through the intact skin and bone at wavelengths ranging from 470 to 655 nm. Expression of ReaChR in the facial motor nucleus of the brainstem allowed us to reliably activate vibrissa motoneurons with wavelengths up to 655 nm through the non-invasive placement of a light-emitting diode (LED) at the opening of the external auditory canal. Thus, ReaChR enables effective and temporally precise noninvasive stimulation of deep brain structures with ChR technology.
RESULTS

Development of a red-activatable ChR
The red-shifted ChR VChR1 (ref. 14) , which has minimal trafficking to the membrane as well as poor expression in mammalian cells 11, 15 , served as a template to engineer an efficient red light-activated ChR. To improve membrane trafficking, we examined the superior membrane trafficking of the variant ChIEF 7 , which gives almost exclusive plasma membrane expression with minimal cytosolic aggregation in mammalian cells without the need for additional trafficking signals, unlike many other ChR variants ( Supplementary Fig. 1 ) 15 . We thus replaced the N terminus of VChR1 before the first transmembrane domain with the corresponding ChIEF sequence. The new construct, denoted C-VChR1, had considerably improved membrane trafficking 15 (P < 0.001 for VChR1 compared to C-VChR1). To increase the expression level, we replaced transmembrane domain F of VChR1 with the corresponding VChR2 helix, a strategy that has been shown previously to increase the expression level of ChR in ChR1-ChR2 chimeras 16 . This new variant, named VCOMET for VChR optimized for membrane expression and trafficking, had a red-shifted response spectra similar to that of C-VChR1 or VChR1 15 , with spectral peaks at 590 and 530 nm for the maximum and steady-state (also called plateau) responses, respectively (Supplementary Fig. 2b ). VCOMET expressed strongly in mammalian cells and retained robust membrane trafficking (Supplementary Fig. 1 ). It also yielded greater photocurrent in HEK293 cells (39 ± 8 pA pF −1 (mean ± s.e.m.), n = 13) compared to C-VChR1 (6.9 ± 1.0 pA pF −1 , n = 13; P < 0.01) and comparable photocurrents to mammalian codon-optimized ChEF t e C h n I C a l r e p O r t S (oChEF; 48 ± 8 pA pF −1 , n = 12; Supplementary Fig. 2a ) and mammalian codon-optimized ChIEF (oChIEF; 52 ± 7 pA pF −1 , n = 7). VCOMET had a reversal potential (12 ± 2 mV (mean ± s.e.m.), n = 8) that was significantly higher than that of oChIEF (4 ± 1 mV, n = 5; P < 0.05) but not that of the calcium-translocating ChRs, CatChs 17 (5 ± 1 mV, n = 6) in physiological saline (H = 10.39, k = 4, P = 0.0155 for comparisons between VCOMET, ChIEF, CatCh and ReaChR) and a reduced inward rectification similar to that of oChIEF ( Supplementary Fig. 2c ) 7 .
Although VCOMET responded strongly to light above 600 nm ( Supplementary Fig. 2b) , the responses at these longer wavelengths were desensitizing and did not recover completely in the dark without reconditioning with 410 nm light (Supplementary Fig. 3 ). We thus sought to reduce the desensitization of VCOMET to light above 600 nm through known point mutations of ChRs. The ChETA mutation 17 did not red shift or reduce the desensitization of VCOMET. The corresponding H134R mutation of ChR2 (ref. 18 ) slowed the channel kinetics and thus degraded the temporal fidelity of the ChR. One mutation, L171I (Fig. 1a) , which corresponds to the same position of the ChIEF mutation 7 , increased the amplitude of the photoresponse at both 610 and 630 nm light through reduced desensitization while retaining the membrane trafficking and expression of VCOMET (Figs. 1 and 2 and Supplementary Fig. 4 ) and thus led to an increase in the steady-state (plateau) spectral peak at 630 nm (Fig. 1f) . This formed ReaChR, the new ChR. ReaChR retained the reversal potential (7 ± 4 mV, n = 6), reduced inward rectification and photocurrent amplitude (34 ± 4 pA pF −1 , n = 9) of VCOMET ( Fig. 1b-d) . The one limitation of ReaChR relative to C-VChR1 was the slower channel closure rate after termination of the light pulse: τ 1/e = 137 ± 7 ms (mean ± s.e.m. n = 11) for ReaChR compared to τ 1/e = 85 ± 4 ms (n = 9) for C-VChR1 (P < 0.05) (Fig. 2d and Table 1 ).
Comparisons of red-shifted ChR variants in cell culture
The ChR variant C1V1 E122T has been shown to excite the neuronal membrane potential with 630 nm light that is pulsed for 50 ms 11 . To gauge the potential benefit of ReaChR over C1V1 and related constructs, we characterized the attributes of ReaChR in comparison to those of C1V1, C1V1 E122T and VCOMET ( The mean photocurrent amplitudes of C-VChR1 (n = 13), C1V1 (n = 10), C1V1 E122T (n = 10), VCOMET (n = 13) and ReaChR (n = 9) recorded from HEK293 cells. The current amplitudes were measured at the wavelengths that evoked the greatest response in each variant and were normalized to cell capacitance. The data in c and d are shown as the mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, Kruskal-Wallis test with post-hoc Dunn's test performed on all pairs of variants (only significant differences detected with Dunn's tests with VCOMET or ReaChR are shown; the statistical tests shown in d also include comparison to oChEF (n = 12) and oChIEF (n = 7)). H = 31.63, k = 5, P < 0. (f) The spectra of the maximum response (left) and steady-state (plateau) response (right) of C-VChR1 (n = 7), C1V1 E122T (n = 8) and ReaChR (n = 7). The responses were normalized to the maximum response of each cell. The gray regions highlight the response above 600 nm. The data in f are shown as the mean ± s.e.m.
npg t e C h n I C a l r e p O r t S neither C1V1 nor C1V1 E122T trafficked to the membrane as well as ReaChR or VCOMET in these cells, and they both showed high amounts of intracellular aggregation and strong cytosolic fluorescence (Fig. 1b,c) . The mean photocurrent of C1V1 expressed in HEK293 cells (13 ± 3 pA pF −1 , n = 10) was smaller than those for VCOMET and ReaChR (Fig. 1d) , possibly because of reduced efficiency in trafficking to the plasma membrane (Fig. 1c) . Introduction of the E122T mutation to form C1V1 E122T reduced the C1V1 photocurrent ~66% (4 ± 1 pA pF −1 , n = 10; Fig. 1d ), although its action spectrum was red shifted, with peaks at 590 and 610 nm for the maximum and steady-state (plateau) responses, respectively (Fig. 1e,f) . The channel kinetics of C1V1 E122T were significantly slower than those of VCOMET and C-VChR1, with a channel closure time constant of τ 1/e = 315 ± 26 ms (n = 8), although this value is similar to that of the parent construct, C1V1 (τ 1/e = 306 ± 10 ms, n = 6; Fig. 2d ). The activation kinetics of C1V1 E122T were also 1.5-to 3-fold slower than ReaChR and C-VChR1 at the same light intensities for 610 and 630 nm light (Fig. 2c) . However, the photocurrent amplitudes of C-VChR1, ReaChR and C1V1 E122T showed similar functional forms in response to incident light intensity ( Supplementary Fig. 4 ). With C-VChR1, C1V1 E122T and ReaChR, increasing the stimulation intensity of 610 nm light led to reduction of the steady-state (plateau) response amplitudes at higher light intensities ( Fig. 2a and Supplementary Fig. 4 ). As ReaChR has improved membrane trafficking, greater photocurrents and faster kinetics compared to C1V1 E122T , we propose that ReaChR is a robust means to stimulate neurons with red-orange to red light.
Comparison of ChR variants in cultured neurons
We compared the properties of ReaChR with those of other ChR variants in cultured neurons 20 . ReaChR traffics to the membrane well and expresses strongly in neurons (n = 22), as we observed in HEK293 cells (Fig. 3a) . The variants C1V1 E122T (n = 13) and C1V1 E122T with an additional trafficking sequence, denoted C1V1 E122T -TS (n = 17) 11, 20 , trafficked to the membrane as well as ReaChR in cultured neurons (Fig. 3a,b) , which is in contrast to the relatively greater trafficking that we observed for ReaChR in HEK293 cells. However, the expression levels of C1V1 E122T and C1V1 E122T -TS were approximately 80-84% lower than those of ReaChR under identical conditions (Fig. 3a,b) . We observed occasional cells with high expression levels of C1V1 E122T and C1V1 E122T -TS, although they occurred too infrequently to be of general utility.
In order to compare the photocurrent amplitudes of different ChR variants, we used a titer-matched lentivirus with a truncated human synapsin 1 Light intensity (mW mm Channel on rate, τ 1/e (ms), 610 nm at 7.6 mW mm -2
Channel on rate, τ 1/e (ms), 630 nm at 7.6 mW mm -2 Channel off rate, npg t e C h n I C a l r e p O r t S promoter (hSyn) to express enhanced yellow fluorescent proteintagged human codon-optimized ChR2 H134R (hChR2 H134R -eYFP), oChIEF-Citrine, C1V1 E122T -TS-Citrine and ReaChR-Citrine in cultured neurons. We selected cells for recording on the basis of their morphology under bright-field visualization. We did not use fluorescence signal-based selection or the selective α-CamKIIα promoter 20 to avoid bias in the selection process. In all cases, ChRs were activated by 10 mW mm −2 of light at the respective maximum response wavelengths. We recorded the photocurrents under voltage clamp. We observed that currents from ReaChR-Citrine-expressing cells (219 ± 50 pA, n = 16) were greater than those from hChR2 H134R -expressing (37 ± 21 pA, n = 16) and C1V1 E122T -TS-expressing (23 ± 11 pA, n = 14) neurons but were non-significantly greater than those from oChIEF-expressing neurons (75 ± 31 pA, n = 17) (Fig. 3c) .
None of the ReaChR-expressing cells tested were unresponsive to light, whereas many hChR2 H134R -expressing (n = 9) and C1V1 E122T -TS-expressing (n = 5) neurons had no detectable response to light.
To test the utility of ReaChR to induce suprathreshold depolarization in neurons, we recorded cells under a current clamp without blockers of voltage-gated channels. We injected current through the patch pipette to maintain the membrane potentials of all cells at −65 mV; we did not correct junction potentials. In ReaChR-expressing neurons, we were able to achieve suprathreshold depolarization with blue (470 nm), red-orange (617 nm) and red light (627 nm) in response to 1s light pulses (Fig. 3d) . The amount of depolarization and the spike-delayed time were dependent on wavelength, light intensity and expression level, in addition to the membrane properties of the neurons (cell type, membrane resistance and capacitance). Cells expressing ReaChR retained normal morphological appearances and physiological membrane properties ( Supplementary Fig. 5 ), suggesting minimal toxic effects with expression. With 617 nm light, we were able to achieve 25-45 mV depolarization (mean, 35 mV) in the expressing cells ( Fig. 3e) and trigger action potentials with a 7-40 ms delay time (mean, 15 ms; Fig. 3f ) when stimulated at a high light intensity (n = 14). With 627 nm light, we were able to achieve 24-44 mV depolarization (mean, 34 mV; npg t e C h n I C a l r e p O r t S Pulsed illumination at 10 Hz was an effective trigger for spiking in ReaChR-expressing neurons at 470, 617 and 627 nm (Fig. 4a) . Light pulses of weak intensity and short duration often lead to loss of temporal fidelity from insufficient depolarization (Fig. 4b) . Light pulses of too high an intensity lead to extra action potentials and depolarization block as a result of insufficient repolarization between light pulses, which were the main reasons for the loss in temporal fidelity that we observed (Fig. 4c) . In addition to stimulation intensity and pulse duration, cell membrane properties and the expression level of ReaChR also affect the ability to trigger action potentials in response to pulsed light. Thus, one specific stimulation protocol that achieved complete fidelity in one ReaChR-expressing cell, for example, 0.5 ms of 5 mW mm −2 of 617 nm light or 1 ms of 10 mW mm −2 of 627 nm light, could fail to trigger action potentials in another cell with different membrane properties and expression levels. We observed this same phenomenon with stimulation at 5 Hz (Supplementary Fig. 6 ).
With regard to the fidelity of spike generation in neurons with ChR variants other than ReaChR, we observed lower firing reliabilities with hChR2 H134R -expressing cells in response to 470 nm light. This variant introduced a high amount of channel desensitization that led to subthreshold depolarization with light pulses toward the end of a pulse train (Fig. 4a) . As the overall amount of depolarization that we observed with hChR2 H134R was lower, extra spiking was rare. Cells expressing oChIEF had the highest temporal precision, as measured by the percentage of pulses achieving suprathreshold depolarization, the shortest spike delay and a variability in spike latency (Fig. 4b-e) , and this higher fidelity was sustained at higher stimulation frequencies (Supplementary Fig. 6 ). Yet even with oChIEF, we observed npg t e C h n I C a l r e p O r t S extra action potentials after strong depolarization in cells with high expression. The spike latency and variability were similar between ReaChR and hChR2 H134R , with a higher variability in the responses to stimulation pulses present later in the pulse train.
Excitation of ReaChR-expressing neurons in vivo
As red light can penetrate mammalian tissues in vivo with less attenuation compared to blue or green light 12 , we used ReaChR to stimulate deep brain structures in vivo. We targeted two areas for in vivo stimulation: vM1, which is involved in the control and execution of vibrissa motion 21 , and the facial motor nucleus of the seventh cranial nerve, whose motoneurons innervate the muscles that are responsible for vibrissa movements. We incorporated ReaChR-Citrine into a recombinant adeno-associated virus (rAAV) with a hSyn promoter and injected it into either vM1 or the facial motor nucleus of individual mice. We confirmed ReaChR expression in vM1 3 weeks after injection. We head fixed the mice and monitored vibrissae movements with high-speed video either during light anesthesia with 1.0-1.5% (vol/vol) isoflurane or while the mice were awake (Fig. 5) . For electrophysiological recordings, we removed the bone over vM1, mapped the zone of infection with epifluorescence imaging of the cortical surface and positioned a 617 nm LED 10 mm above the surface of the brain (Fig. 5a,b) . We used short pulses of light, 1-20 ms in duration, to activate ReaChR-expressing neurons (Fig. 5c ) and evoke spikes, as recorded extracellularly (Fig. 5d-f) . ReaChR-expressing vM1 neurons (m) Absolute movement amplitudes evoked by 100 ms pulses of 470, 617 and 655 nm light through intact skin in ReaChR-expressing mice (n = 3 mice, ten stimulus repetitions per condition per mouse). Additionally, three mice injected with viral vehicle solution (mock control) were stimulated through the skin with 617 nm light (black). (n) Boxplots of movements during the first second after vM1 photoactivation through the intact skull of mock-transduced (veh, black; n = 3 mice; 617 nm illumination) and ReaChR-expressing mice (n = 3 mice; 470-655 nm wavelengths). Vertical lines indicate the data range, boxes indicate the 25th to 75th percentile ranges, and the central lines mark the median. ***P < 0.001, one-sided Kolmogorov-Smirnov test. The light intensity used in a-n was 100 mW. 
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were reliably photoactivated at short latencies and with low temporal jitter (Fig. 5d) . The evoked activity of a representative cortical single unit is shown in Figure 5d -f. This unit, which probably expressed ReaChR, fired one or more spikes in response to 2 ms pulses with submillisecond jitter and a short, 2.4 ms spike latency. The unit was reliably activated with trains of light pulses that ranged from 5 to 30 Hz. Increasing the rate of optical activation to greater than 20 Hz resulted in a larger number of extra spikes per pulse (Fig. 5f ). We observed a monotonic increase in the number of evoked spikes and in the spiking probability as a function of stimulus duration (n = 8 single units; Fig. 5g,h ). The spiking probability was above 0.95 when the stimulus duration was 5 ms or longer (Fig. 5h) . When the stimulus rate exceeded 10 Hz, the population response increased (P = 0.002, one-sided Kolmogorov-Smirnov test; Fig. 5i ) and the latency to the first spike decreased (P = 0.01, one-sided KolmogorovSmirnov test ; Fig. 5j) ; these effects probably result from the slow closing kinetics of ReaChR. Consistent with in vivo neural activation of ReaChR-expressing neurons, we found that vibrissae movements could be elicited by LED illumination in awake mice (Fig. 5k-n) . Removal of skin and bone was not required to evoke these movements, and placing the stimulating LEDs 10 mm above the fur line was sufficient in all cases (Fig. 5k) . Movements were elicited with both blue (470 nm) and red (617 and 655 nm) illumination. Evoked movements were characteristic of those observed with electrical stimulation of vM1, showing both a rapid component 22, 23 and a sustained period, albeit with unpredictable duration, of rhythmic whisking that outlasted the stimulus 24 (Fig. 5l,m) .
Our in vivo cortical experiment demonstrated stronger evoked movement responses to 617 nm as compared to 470 nm light (P < 0.0001, one-sided Kolmogorov-Smirnov test; Fig. 5m,n) , which is consistent with the larger responses to orange-red light that we observed in cultured HEK293 cells (Fig. 1f and Supplementary  Fig. 7 ) and the greater attenuation of blue compared to red light in mammalian tissue 12 . We confirmed that these movements were caused by photoactivation of ReaChR by comparison with movements measured in a cohort of mock-transduced mice injected with a viral vehicle (Fig. 5m,n) . Because we were able to evoke movements with 470 nm light in ReaChR-expressing mice, we tested whether movement could be evoked non-invasively with a standard blue light-activated ChR variant. We thus expressed hChR2 H134R -eYFP in vM1 with an identical rAAV vector and viral titer. Vibrissa movements could be evoked in mice expressing hChR2 H134R in vM1 with 470 nm light illumination (n = 3), but these movements were more infrequent, notably smaller (Supplementary Fig. 7c-f) .
The durations and amplitudes of the movements evoked by vM1 stimulation in ReaChR-expressing mice were unpredictable (Fig. 5l) , mirroring the results obtained with electrical stimulation in awake mice 24 but nonetheless complicating comparisons of different stimulation parameters. As a more stringent test of the sensitivity of ReaChR to different wavelengths in vivo, we targeted ReaChR to the mystacial motoneurons in the facial motor nucleus of the brainstem that directly control vibrissa movements (Fig. 6a,b) . It has been shown previously that in deeply anaesthetized mice, direct electrical stimulation of these neurons can reliably drive vibrissa movements, producing a relatively noise-free and controlled behavioral output 25 . In mice, the facial motor nucleus is located at a depth of up to 6 mm in the ventral part of the brainstem. We delivered light at 470, 530, 591, 617, 627 and 655 nm wavelengths in a non-invasive manner by placing an LED at the opening of the external auditory canal, thus illuminating the brainstem at a distance of 8-10 mm from the midline through intact tissue and bone (Fig. 6c) . The external ear canal provides a convenient anchor point for noninvasive LED placement, bypasses fur and provides an opportunity to limit photoactivation to one side of the brainstem. We typically flashed the LEDs for periods of 100 ms at 1 Hz with a 1-100 mW light output; we found no visual indications of any heat-related damage to the outer ear tissue. Activation of ReaChR-expressing neurons elicited highly reproducible and temporally precise vibrissae movements, which is consistent with the direct activation of motoneurons (Fig. 6d,e and Supplementary Video 1) . Although a topographic organization of the facial muscle representation within the facial motor nucleus has been documented, the exact distribution of all the motoneurons innervating muscles that are involved in vibrissa control is not known 26 . Both protraction and retraction of the vibrissae are actively controlled by multiple extrinsic and intrinsic muscles 22, 27 . We found no consistent pattern between the intrafacial motor nucleus locations of infected motoneurons and the evoked movement trajectories, and in several mice, both net protraction and retraction could be elicited by adjusting the light intensity appropriately (Fig. 6d,e) . As an example, Figure 6d shows evoked movements in a mouse in which light stimulation led to the retraction of all vibrissae independently of light intensity (10-100 mW light output, 100 ms pulses; Supplementary Video 2). Evoked retractions were three times larger when ReaChR was activated at 617 nm as compared to 470 nm (40° compared to 13°, respectively, at maximum amplitude). Similarly, light stimulation of a different mouse (Fig. 6e) produced sixfold larger movements at 617 nm compared to 470 nm (19° compared to 3°, respectively, at maximum amplitude). We observed this pattern of stronger activation at 617 nm compared to 470 nm in all ReaChRexpressing mice (Fig. 6f) .
Vibrissa movements in ReaChR-expressing mice could be evoked across a broad range of wavelengths, which is consistent with our in vitro results. The largest movements were evoked at 617 nm, followed by 627 nm and 470 nm. Smaller vibrissa movements were also evoked with 530, 591 and 655 nm illumination (Fig. 6g) . We confirmed that these movements resulted from photoactivation of ReaChR and not LED-related heating of neural tissue or visually evoked responses by the fact that we did not observe any movement in a cohort of mice expressing the blue light-activated hChR2 H134R channel in the facial motor nucleus (n = 15; Fig. 6g and Supplementary  Fig. 7g-i) and by recording single units in the brainstem of ReaChRexpressing mice that reliably responded with short latencies and submillisecond temporal jitter to light stimulation (Fig. 6h) .
The variability in whisking between individual mice in response to illumination of the facial motor nucleus was great (Fig. 6f) . This was probably caused by variations in the exact locations of ReaChRexpressing motoneurons within the facial motor nucleus, which is ~1 mm in width, and/or high expression levels in individual motoneurons that resulted in very low spiking thresholds. In principle, this variability could also be caused by direct stimulation of the facial motor nerve. We confirmed that motoneuron axons were labeled with ReaChR-Citrine and that vibrissa movements could also be evoked by direct illumination of the peripheral motor nerve through the skin of the lower cheek. These movements, however, were smaller and of shorter duration than those evoked through the ear ( Supplementary  Fig. 7a ). In addition, movements were not evoked when stimulating through the ear contralateral to the side of ReaChR expression (617 nm, 100 mW light output), which shows that the lateralization of optogenetically evoked brainstem activity can be controlled with through-skull stimulation (Supplementary Fig. 7b ).
DISCUSSION
The optimal wavelength range for optical imaging into mammalian tissue is near infrared (600-1,300 nm), where light scattering decreases with increasing wavelength and absorption by enodogenous chromophores is reduced, yet absorption by water is still negligible. This paves the way for deeper penetration of light into tissue with reduced attenuation 12 . Optogenetic tools to manipulate neuronal activity should ideally be excited by near-infrared light. Current development of ChRs has produced many new variants that are maximally activated by blue and green light, such as ChR2 H134R , ChETA, TC, SFO D156A , ChD, oChEF, oChIEF, CatCh and ChRGR 7, 8, 10, 17, 18, 28, 29 . Many of these variants have improved properties regarding kinetics, expression and amounts of desensitization compared with native ChR2. However, there has been little progress in the development of red-shifted ChRs.
In this study, we engineered two red-shifted ChR variants, VCOMET and ReaChR, that had strong membrane expression in mammalian cells. The ReaChR variant responded strongly to red light, with a secondary steady-state spectral peak at 630 nm in addition to a primary steady-state spectral peak at ~540 nm. The mechanism for this shift involves the L171I mutation in VCOMET. Past work attributed this position to the red shift of the response spectrum of VChR1 (Leu126) relative to ChR2 (Ile131) 14 , which implies that this L171I modification should lead to a blue shift in the response spectrum. However, this idea is based on the charge distribution of all-trans retinal in the binding pocket of bacteriorhodopsin in the dark state. In bacteriorhodopsin, some transient intermediate photocycle states have absorption spectra above 600 nm, whereas the initial activation of the protein has a λ max value of ~570 nm 30 . It seems that the main effect of the L171I mutation in ReaChR is to extend the lifetime of the redshifted transient states and reduce the desensitization of the transient state, leading to a greater photocurrent to red light. In support of this hypothesis, we found differential spectral peaks with the transient and steady-state responses of C-VChR1 and VCOMET, with the transient states having λ max values of ~570-590 nm and the steady-state having a λ max value of ~530 nm ( Fig. 1f and Supplementary Fig. 2b) .
The initially described red-shifted ChR, VChR1, does not express well in mammalian cells and traffics poorly to the membrane, limiting its utility for in vivo applications 14, 15 . The recently published variant C1V1 and its derivatives have been reported to have improved expression, membrane trafficking and kinetic properties compared to VChR1 (ref. 11). However, in our tests, C1V1 and its variants were still limited in their membrane trafficking and expression compared to VCOMET and ReaChR, in addition to having slower channel kinetics npg t e C h n I C a l r e p O r t S (Figs. 1 and 2) . The most red-shifted C1V1 derivative, C1V1 E122T , has a spectral peak at ~600 nm and slower channel kinetics and limited expression compared with ReaChR (Figs. 1-3) . The E122T mutation variant also has a reduced photocurrent, as has been previously reported 11 , that may result from the position of this residue within the putative channel pore of ChR, as predicted from the crystal structure of ChEF 31 . Thus, the reduction of C1V1 E122T photocurrents and slow kinetics negate the spectral advantage that the E122T mutation provides. In contrast, ReaChR is strongly expressed, consistently traffics to the membrane and can be used to reliably trigger temporally precise spiking.
Although ReaChR has an improved spectral response to light at wavelengths greater than 600 nm, it still suffers slow kinetics in its channel closure rate compared to variants such as ChR2, ChIEF, ChD and ChETA 7, 8, 10, 17, 18, 28, 29 . In the blue light-activated ChR variants, single point mutations that improve the channel kinetics also reduce the channel's light sensitivity 7, 15 . The other known ChR mutation that increased the channel kinetics, E123T of ChR2, E162T of C1V1 and E163T of VCOMET, does so at the expense of reduced light sensitivity and reduced photocurrents 17 . In the context of ReaChR, this E-to-t mutation increases the channel kinetics (off rate <30 ms) and surpasses C1V1 E162T in terms of kinetics 11 but blue shifts the spectral peak to 550 nm (Supplementary Fig. 8 ) and increases the desensitization of the channel. We did not find incorporation of this mutation useful in the current development of ReaChR. Important future goals in developing red-shifted ChR should include improving light sensitivities and faster kinetics simultaneously and reducing the activation of these variants by light below 500 nm to allow for the independent manipulation of two populations of neurons with two different wavelengths of light.
We were able to exploit the spectral advantages of ReaChR to achieve efficient activation of expressing neurons through fur, skin and intact bone of adult mice with red-orange (617 nm), red (627 nm) and even far-red (655 nm) light (Figs. 5 and 6 ). This enables new in vivo applications of transcranial and deep-brain stimulation with optogenetics. Transcranial stimulation is essential for many chronic studies, as cranial windows can lead to activated microglia and astrocytes as part of an inflammatory response 32 that in turn alters neuronal physiology 33 and plasticity 34 , as well as pial vasculature 35, 36 . Alternatives to our approach for non-invasive transcranial stimulation include clinically approved treatments for several neurological disorders and stroke, such as electroconvulsive therapy, repetitive transcranial magnetic stimulation and transcranial direct-current stimulation. These techniques do not, however, have the spatial and cellular specificity that can be achieved through optogenetics. Thus, optogenetic approaches using red-shifted ChRs, such as ReaChR, have the potential to improve the efficiency of transcranial stimulation to treat neurological disorders.
In the present study, we introduced the ChR ReaChR through injections of an engineered virus directly into the region of interest. In future work, it may be possible to label specific populations of neurons by retrograde transport of ReaChR from a known target 37, 38 . For example, pools of motoneurons in the brainstem or the spinal could be labeled by injection into specific muscles rather than into motor nuclei themselves. Such an approach would substantially reduce the invasiveness of an optogenetic strategy for future therapeutic use. Further, one could label opposing muscle groups with short-or long-wavelength ChRs to permit differential optical control of opposing muscle groups. The weak absorption of short wavelengths by ReaChR will not compromise this strategy if the anatomically deeper motor pools are labeled with ReaChR. ReaChR may also facilitate neurological treatment and neuroprosthetic control through transcranial and possibly transvertebral stimulation.
METhODS
Methods and any associated references are available in the online version of the paper. The shuttering and intensity of the light were controlled with a custom-fitted 25 mm mechanical shutter (Vincent Associates, Rochester, NY) and a neutral density wheel (Thorlab, Newton, NJ). For the spectral response measurements and experiments in which the light intensity was not described, cells were stimulated with ~5.1 × 10 16 photon mm −2 s −1 across the light spectra. The photon flux of the monochromator at each wavelength was measured with a power meter and integrating sphere (Newport Corporation, Irvine, CA) placed on the objective, and the photon flux was corrected with the neutral density wheel to give the same flux. The response spectra of the ChRs were measured with a 1 s light pulse from 650 to 410 nm of the same photon flux at 20 nm intervals, with the maximum response taken as the maximal photocurrent obtained within the 1 s pulse at the described wavelength, and the steady-state response was measured between 0.95-1.00 s after the onset of the stimulation light pulse. For most experiments, 410 nm light was delivered 20 s after the initial stimulation to recondition the protein before the delivery of the next testing pulse 20 s later. Stimulation of neurons under the current clamp was conducted with 470 nm (SR-05-B0040), 617 nm (SR-05-H2070) or 627 nm (SR-05-D2050) LED illumination (Luxeonstar, Brantford, Ontario, Canada). The LEDs were connected to a computer-controlled current source (Mightex, Pleasanton, CA) coupled to a quartz fiber into the microscope. expression and stimulation of chR-expressing neurons in vivo. Recombinant AAV2/8-hSyn-ReaChR-Citrine or AAV2/8-hSyn-hChR2 H134R -eYFP virus was injected stereotaxically into the vibrissa motor cortex (vM1) or the facial motor nucleus in the brainstem of C57BL/6 female mice using a nanoliter injector (Nanoject II, Drummond, Broomall, PA) under isoflurane anesthesia (2% (vol/vol)). The injection coordinates for vM1 were 1 mm posterior, 1 mm lateral and 0.8 mm ventral, and the coordinates for the facial motor nucleus were 4.8-5.6 mm posterior, 1.2-1.4 mm medial and 5.3-6.0 mm ventral to the bregma. The skin was retracted to expose the injection coordinates, and a single 0.3 mm diameter hole was drilled for each injection site. Suspension of virus was injected in ten 50 nl aliquots every 5 min (total volume, 500 µl) in vM1 and in five 12 µl aliquots (total volume, 60 µl) every 5 min in the facial motor nucleus. The injection hole was filled with sterile saline and topped with a thin layer of antibiotic ointment after the injection pipette was withdrawn. The skin was sutured back in place, and the mouse was left to recover for the viral incubation period. After a waiting period of 4 weeks, the mice were prepared for in vivo experiments. The injections of virus were done on 3-month-old mice, and the tests were performed 3-6 weeks later. All mice were housed on a normal 12 h light, 12 h dark cycle in groups of between 3 and 5 mice per cage, and all mice were tested during the light cycle.
One day before the experiments, a single 10 mm incision was made perpendicular to the midline and caudal to lambda, the skull was exposed, and a titanium alloy head bar was attached to the skull using cyanoacrylate gel and a layer of dental cement (C&B-Metabond, Parkell Inc., Edgewood, NY) during isoflurane anesthesia. The skin rostral to the lambda was not damaged, and the skull under it was neither exposed nor covered by any amount of cement, except for during the electrophysiological recordings in vM1, for which a new craniotomy was opened where the virus had been injected previously. Over the next several daysmice were head fixed either when awake or during isoflurane anesthesia (0.5-2%), as indicated. ReaChR was activated in vivo by LEDs with wavelengths of 470 nm (LXML-PB01-0030), 530 nm (LXML-PM01-0100), 591 nm (LXM2-PL01-0000), 617 nm (LXM2-PH01-0070), 627 nm (LXM2-PD01-0050) and 655 nm (LXM3-PD01-0260, Luxeonstar, Brantford, Ontario, Canada) connected to a computercontrolled current source (Mightex, Pleasanton, CA).
Single units in vM1 and the facial motor nucleus were recorded extracellularly with 9-12 MΩ tungsten electrodes (UEWLCESMLN1G, FHC Inc., Bowdoin, ME), buffered, preamplified (Alpha Omega Co., Alpharetta, GA) and acquired onto a personal computer (PCIe-6361, National Instruments, Austin, TX) using custom-written software for Matlab (MathWorks, Natick, MA). Spikes were sorted using the Chronux library in Matlab (http://chronux.org).
Vibrissa movements were monitored with high-speed video 36 and tracked offline using the WhiskerTracker software 40 (code available at https://github.com/ pmknutsen/whiskertracker). After in vivo experiments, the mice were perfused with 4% paraformaldehyde, the brains were extracted, and ReaChR expression was confirmed with epifluorescence imaging and localized histologically using a fluorescent Nissl counterstain (NeuroTrace N21479, Life Technologies, Carlsbad, CA). The bone overlying the injection sites was inspected after perfusions and was invariably found to have regrown entirely. In most mice, the bone that had regrown after viral injections appeared thickened. Only mice with ChR expression in the correct regions identified with postmortem histochemical analysis were included in the analysis of spiking and vibrissae movement. Although the experimenter was not blinded to group status, the measurement was automated, so blinding status would not affect the outcome of the experiment. All animal procedures, including the extraction of primary neurons, were approved by the UCSD Institutional Animal Care and Use Committee. 
